SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01261312
Recruitment Status : Completed
First Posted : December 16, 2010
Last Update Posted : September 21, 2018
Information provided by (Responsible Party):
Astex Pharmaceuticals